Moberg Pharma divests Balmex for 4.25 million dollars
Moberg Pharma AB has entered into an agreement with Randob Labs to divest the brand Balmex® for a total consideration of $4.25 million (34.6 million SEK) plus the inventory value at closing.
The divestment is expected to result in a capital gain of circa $0.5 million (4.4 million SEK), enabling Moberg Pharma to further focus resources on its larger brands.
The brand Balmex®, with a number of products for treating and preventing diaper rash, was acquired from Chattem Inc. in April 2015. The role of Balmex® in the product portfolio has reduced after the 2016 acquisitions.
Divesting the brand enables Moberg Pharma to focus resources on its larger and more profitable brands. The brand generated net sales of $3.8 million(32.8 million SEK) in 2017.
The transaction is expected to close in April.
"We are pleased with the divestment. We have now successfully divested most of our minor brands, enabling us to focus our resources on growing our larger brands", says Peter Wolpert, CEO Moberg Pharma.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd